Literature DB >> 26279697

Ga68-DOTA Peptide PET/CT to Detect Occult Mesenchymal Tumor-Inducing Osteomalacia: A Case Series of Three Patients.

Chi Long Ho1.   

Abstract

Tumor-induced osteomalacia (TIO) is a rare disease that manifests with paraneoplasic syndrome and overproduction of fibroblast growth factor 23 (FGF23), leading to renal phosphate wasting and hyperphosphaturia, eventually leading to acquired hypophosphatemic osteomalacia. Diagnosis of this disease is often challenging because of the small size of the lesion, which can be localized in bone or soft tissue anywhere in the body. Detecting these occult mesenchymal tumors (OMT) is of great importance as they are potentially curable after tumor resection. The purpose of this case series is to provide some insight into the diagnosis and localization of OMT associated with osteomalacia, particularly using functional imaging with Ga68-DOTA peptide PET/CT scans.

Entities:  

Keywords:  Fibroblast growth factor 23; Ga68-DOTA peptide or DOTANOC PET/CT; Occult mesenchymal tumor; Tumor-induced osteomalacia

Year:  2015        PMID: 26279697      PMCID: PMC4532688          DOI: 10.1007/s13139-015-0328-2

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  15 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

2.  Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography.

Authors:  Eric Hesse; Eckart Moessinger; Herbert Rosenthal; Florian Laenger; Georg Brabant; Thorsten Petrich; Klaus F Gratz; Leonard Bastian
Journal:  J Bone Miner Res       Date:  2007-01       Impact factor: 6.741

3.  Oncogenic osteomalacia associated with an occult phosphaturic mesenchymal tumour: clinico-radiologico-pathological correlation and ultrastructural studies.

Authors:  F M F Cheung; L Ma; W C Wu; T H Siu; P T Choi; Y P Tai
Journal:  Hong Kong Med J       Date:  2006-08       Impact factor: 2.227

4.  Determination of the elimination half-life of fibroblast growth factor-23.

Authors:  Azarmindokht Khosravi; Carolee M Cutler; Marilyn H Kelly; Richard Chang; Richard E Royal; Richard M Sherry; Felasfa M Wodajo; Neal S Fedarko; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2007-03-20       Impact factor: 5.958

5.  Tumor-induced osteomalacia: a single center experience.

Authors:  Varsha S Jagtap; Vijaya Sarathi; Anurag R Lila; Gaurav Malhotra; Shilpa S Sankhe; Tushar Bandgar; Padmavathy Menon; Nalini S Shah
Journal:  Endocr Pract       Date:  2011 Mar-Apr       Impact factor: 3.443

6.  Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients.

Authors:  Swati Jadhav; Rajeev Kasaliwal; Vikram Lele; Venkatesh Rangarajan; Piyush Chandra; Hina Shah; Gaurav Malhotra; Varsha S Jagtap; Sweta Budyal; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Clin Endocrinol (Oxf)       Date:  2014-03-12       Impact factor: 3.478

7.  Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.

Authors:  Michèle Duet; Samar Kerkeni; Raja Sfar; Cécile Bazille; Frédéric Lioté; Philippe Orcel
Journal:  Clin Nucl Med       Date:  2008-11       Impact factor: 7.794

8.  Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature.

Authors:  Andrew L Folpe; Julie C Fanburg-Smith; Steven D Billings; Michele Bisceglia; Franco Bertoni; Justin Y Cho; Michael J Econs; Carrie Y Inwards; Suzanne M Jan de Beur; Thomas Mentzel; Elizabeth Montgomery; Michal Michal; Markku Miettinen; Stacey E Mills; John D Reith; John X O'Connell; Andrew E Rosenberg; Brian P Rubin; Donald E Sweet; Tuyethoa N Vinh; Lester E Wold; Brett M Wehrli; Kenneth E White; Richard J Zaino; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2004-01       Impact factor: 6.394

9.  Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue.

Authors:  Naoki Uramoto; Mitsuru Furukawa; Tomokazu Yoshizaki
Journal:  Auris Nasus Larynx       Date:  2008-03-07       Impact factor: 1.863

Review 10.  Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.

Authors:  Fang-Ke Hu; Fang Yuan; Cheng-Ying Jiang; Da-Wei Lv; Bei-Bei Mao; Qiang Zhang; Zeng-Qiang Yuan; Yan Wang
Journal:  Chin J Cancer       Date:  2011-11
View more
  10 in total

1.  Imaging features of phosphaturic mesenchymal tumors.

Authors:  Stephen M Broski; Andrew L Folpe; Doris E Wenger
Journal:  Skeletal Radiol       Date:  2018-07-09       Impact factor: 2.199

2.  Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours.

Authors:  Marie Paquet; Mathieu Gauthé; Jules Zhang Yin; Valérie Nataf; Ophélie Bélissant; Philippe Orcel; Christian Roux; Jean-Noël Talbot; Françoise Montravers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-12       Impact factor: 9.236

3.  68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia.

Authors:  Diala El-Maouche; Samira M Sadowski; Georgios Z Papadakis; Lori Guthrie; Candice Cottle-Delisle; Roxanne Merkel; Corina Millo; Clara C Chen; Electron Kebebew; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2016-08-17       Impact factor: 5.958

4.  Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management.

Authors:  Deepa Singh; Aditi Chopra; Mudalsha Ravina; Srikant Kongara; Eesh Bhatia; Narvesh Kumar; Sushil Gupta; Subhash Yadav; Preeti Dabadghao; Rajnikant Yadav; Veeresh Dube; Utham Kumar; Manish Dixit; Sanjay Gambhir
Journal:  Br J Radiol       Date:  2017-02-09       Impact factor: 3.039

5.  Phosphaturic Mesenchymal Tumors from Head to Toe: Imaging Findings and Role of the Radiologist in Diagnosing Tumor-Induced Osteomalacia.

Authors:  Ameya S Kawthalkar; Amit K Janu; Mrunmayee S Deshpande; Kunal B Gala; Ashish Gulia; Ajay Puri
Journal:  Indian J Orthop       Date:  2020-01-13       Impact factor: 1.251

6.  Extended Whole-body Ga-68 DOTATATE PET-CT in evaluating Tumour-Induced Osteomalacia: Case report and review of literature.

Authors:  Teik Hin Tan; Ew-Jun Chen; Ming Tsuey Chew; Ping Ching Chye; Ming Wong
Journal:  Nucl Med Mol Imaging       Date:  2021-04-19

7.  Phosphaturic mesenchymal tumor: Case report.

Authors:  Adam L Richardson; Olivia K Richardson
Journal:  Radiol Case Rep       Date:  2019-10-22

8.  Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome.

Authors:  S Kumar; T Diamond
Journal:  Bone Rep       Date:  2020-05-06

Review 9.  Phosphaturic mesenchymal tumors: radiological aspects and suggested imaging pathway.

Authors:  Mohsin A M Hussein; Francesco Pio Cafarelli; Maria Teresa Paparella; Winston J Rennie; Giuseppe Guglielmi
Journal:  Radiol Med       Date:  2021-08-28       Impact factor: 3.469

Review 10.  Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors.

Authors:  Rasmus Helgebostad; Mona-Elisabeth Revheim; Kjersti Johnsrud; Kristine Amlie; Abass Alavi; James Patrick Connelly
Journal:  Diagnostics (Basel)       Date:  2022-02-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.